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Abstract 
Background: The aim of this study was to determine the impact of metabolic syndrome (MetS) on lipid target 
achievements in the Arabian Gulf.
Methods: The centralized pan‑middle east survey on the undertreatment of hypercholesterolemia (CEPHEUS) 
included 4171 high and very high atherosclerotic cardiovascular disease (ASCVD) risk patients from six Arabian Gulf 
countries. Analyses were performed using univariate statistics.
Results: The overall mean age was 57 ± 11 years, 41 % were females and 71 % had MetS. MetS patients were less 
likely to attain their HDL‑C (34 vs. 79 %; P < 0.001), LDL‑C (27 vs. 37 %; P < 0.001), non HDL‑C (35 vs. 55 %; P < 0.001) 
and Apo B (35 vs. 54 %; P < 0.001) compared to those without MetS. Within the MetS cohort, those with very high 
ASCVD risk were less likely to attain their lipid targets compared to those with high ASCVD risk [HDL‑C (32 vs. 41 %; 
P < 0.001), LDL‑C (24 vs. 43 %; P < 0.001), non HDL‑C (32 vs. 51 %; P < 0.001) and Apo B (33 vs. 40 %; P = 0.001)]. In 
those with MetS and very high ASCVD risk status, females were less likely to attain their HDL‑C (27 vs. 36 %; P < 0.001), 
LDL‑C (19 vs. 27 %; P < 0.001) and Apo B (30 vs. 35 %; P = 0.009) compared to males.
Conclusions: MetS was associated with low lipid therapeutic targets. Women and those with very high ASCVD risk 
were also less likely to attain their lipid targets in the Arabian Gulf.
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Background
The prevalence of metabolic syndrome (MetS) in the gen-
eral population is 10–15  % higher in the Arabian Gulf 
than in most developed countries and is more observed 
in women (32.1–42.7 %) than men (20.7–37.2 %) [1]. Sim-
ilarly, MetS is also highly prevalent (46 %) in patients with 
acute coronary syndrome (ACS) in the Arabian Gulf [2, 
3]. MetS is associated with increased risk of developing 
type 2 diabetes mellitus (T2DM), cardiovascular disease 
(CVD) and mortality [4, 5]. In the Gulf Registry of Acute 
Coronary Events (Gulf RACE), which included 8716 con-
secutive patients hospitalized with ACS in six Arabian 
Gulf countries, MetS was associated with increased risk 
for the development of heart failure and recurrent myo-
cardial ischemia without an increase in hospital mortality 
[2].
The atherogenic dyslipidemia in MetS is characterized 
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elevated triglyceride (TG) and increased concentration 
of small, dense low-density lipoprotein (LDL) particles. 
Lifestyle therapy to improve atherogenic lipid profile 
should be recommended to all subjects with MetS [6] and 
if therapeutic lipid targets are not achieved then maxi-
mally tolerated statins or combination therapies should 
be recommended depending on risk stratification [5].
Despite the high prevalence of MetS and dyslipidemia 
in the Arabian Gulf region, there are currently no pub-
lished data assessing the gap in the treatment of dyslipi-
demia in patients with MetS. Hence, the objective of this 
study was to evaluate the impact of MetS on lipid target 
achievements among patients with high and very high 
atherosclerotic cardiovascular disease (ASCVD) risk 
status in the Centralized Pan-Middle East Survey on the 
undertreatment of hypercholesterolemia (CEPHEUS) in 
the Arabian Gulf.
Methods
The study has been previously described [7]. Briefly, the 
CEPHEUS study was a multi-centre non-interventional 
survey of patients on lipid lowering drugs (LLDs) in six 
Middle Eastern countries (Saudi Arabia, United Arab 
Emirates, Oman, Qatar, Bahrain, Kuwait). A total of 5457 
patients were enrolled in this survey from outpatient 
clinics by 177 specialists and primary care physicians. 
The study was conducted between November 22, 2009 
and July 7, 2010. The inclusion criteria were: patients 
≥18  years of age; taking LLDs for ≥3  months, with no 
dose change for a minimum of 6 weeks.
A fasting blood sample was taken from each subject 
for measurement of total cholesterol (TC), HDL-C, low-
density lipoprotein cholesterol (LDL-C), TG, apolipo-
protein A1 (Apo A1), apolipoprotein B (Apo B), glucose 
and glycated haemoglobin A1c (HbA1c). Blood samples 
were collected in 3 tubes (5  ml in a gel tube, 2  ml in a 
potassium oxalate/sodium fluoride tube and 2  ml in an 
ethylenediaminetetra-acetic acid (EDTA) tube. The blood 
samples were shipped by air courier and the tests were 
performed at the King Faisal specialist Hospital and 
Research Centre (Riyadh, Saudi Arabia). All the labora-
tory tests underwent internal and external quality con-
trol checks. Criteria for ASCVD risk status was derived 
from the National Lipid Association (NLA) recommen-
dations for patient-centered management of dyslipidemia 
part 1—executive summary [8]. High risk group included 
patients with ≥3 major ASCVD risk factors, diabetes 
mellitus (type 1 or 2) with 0–1 other major ASCVD risk 
factor or LDL-C ≥190  mg/dL (5.02  mmol/L) (severe 
hypercholesterolemia). Very high risk group included 
ASCVD and diabetes mellitus with ≥2 other major 
ASCVD risk factors [8].
As per recent unified definition by the International 
Diabetes Federation (IDF) and the American Heart Asso-
ciation/National Heart, Lung and Blood Institute (AHA/
NHLBI) using the modified National Cholesterol Edu-
cation Program–Adult Treatment Panel III (NCEP ATP 
III) guidelines [9], metabolic syndrome was defined as 
having 3 or more of the following criteria: (1) increased 
abdominal obesity (waist circumference of ≥94  cm for 
men and ≥80 cm for women for Middle Eastern (Medi-
terranean/European) populations), (2) elevated triglyc-
erides of ≥150 mg/dL (1.7 mmol/L), (3) reduced HDL-C 
of <40  mg/dL (1.0  mmol/L) for males and <50  mg/dL 
(1.3  mmol/L) for females, (4) elevated BP ≥130  mmHg 
for systolic and/or ≥85 mmHg for diastolic, and (5) ele-
vated fasting blood glucose of ≥100 mg/dL (5.6 mmol/L).
Therapeutic lipoprotein targets for the high ASCVD 
risk patients were LDL-C <2.6 mmol/L (100 mg/dL) and 
LDL-C <1.8 mmol/L (70 mg/dL) for those with high and 
very high ASCVD risk status, respectively [8]. Blood 
pressure (BP) goals were adapted from the new Eighth 
Joint National Committee (JNC-8) 2014 Hypertension 
Guideline Management Algorithm. BP goals for those 
without diabetes mellitus (DM) and ≥60 years and those 
<60  years were <150/90  mmHg and <140/90  mmHg, 
respectively. For those with DM irrespective of age, the 
BP goal was <140/90 mmHg [10].
Statistical analysis
Descriptive statistics were used to describe the data. For 
categorical variables, frequencies and percentages were 
reported. Differences between groups were analyzed 
using Pearson’s χ2 tests (or Fisher’s exact tests for cells 
<5). For continuous variables, mean and standard devia-
tion were used to summarize the data. Analyses were 
performed using Student’s t test. An a priori two-tailed 
level of significance was set at 0.05. Statistical analyses 
were conducted using STATA version 13.1 (STATA Cor-
poration, College Station, TX, USA).
Ethics approval
This study complied with the declaration of Helsinki 
and had approval from the internal review bodies/ethics 
committees of each participating institution in each of 
the Arabian Gulf countries (CEPHEUS; Study Code: SRP-
CB-CRE-2006/01). Informed written consent was also 
obtained from all patients enrolled in the study.
Results
In total, 5457 patients participated in the survey. How-
ever, those that had missing laboratory data, underage 
(<18 years), missing risk level data as well as those with 
low and moderate risk were not included in this study. 
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Therefore, the final study sample comprised of 4171 high 
and very high ASCVD risk patients.
Table 1 outlines the demographics and clinical charac-
teristics of the cohort. The overall mean age of the cohort 
was 57 ± 11 years with 41 % (n = 1711) females and 77 % 
(n  =  3215) Arab Gulf citizens. The average body mass 
index (BMI) was 31 ± 7 kg/m2. The proportion of patients 
with coronary heart disease (CHD), diabetes mellitus and 
hypertension were 36 % (n = 1511), 77 % (n = 3205) and 
70 % (n = 2906), respectively. Most of the patients (78 %; 
n  =  3261) had very high ASCVD risk status. Majority 
(94 %; n = 3928) were on statin monotherapy. Patients on 
statin combination and other dyslipidemic therapy were 
4.8 % (n = 202) and 1.0 % (n = 41), respectively.
MetS patients were more likely to be female (46 vs. 
30 %; P < 0.001), associated with higher waist circumfer-
ence (106 vs. 99 cm; P < 0.001) and BMI (32 vs. 29 kg/m2; 
P < 0.001), hypertensive (73 vs. 62 %; P < 0.001), diabetic 
(83 vs. 63 %; P < 0.001) and very high ASCVD risk status 
(81 vs. 73 %; P < 0.001). MetS patients were also less likely 
to attain HDL-C (34 vs. 79 %; P < 0.001), LDL-C (27 vs. 
37 %; P < 0.001), Apo B (35 vs. 54 %; P < 0.001) and non 
HDL-C (35 vs. 55 %; P < 0.001) lipid targets.
Figure  1 shows that the number of patients with 1, 2, 
3, 4 and 5 MetS risk factors were 7.0 % (n = 291), 21 % 
(n =  888), 32 % (n =  1339), 26 % (n =  1087) and 13 % 
(n = 522), respectively. Figure 2 outlines the lipid target 
achievements (HDL-C, LDL-C, non HDL-C and Apo B) 
in metabolic syndrome patients stratified by ASCVD risk 
status. MetS patients with very high ASCVD risk status 
were less likely to attain HDL-C (32 vs. 41 %; P < 0.001), 
LDL-C (24 vs. 43 %; P < 0.001), non HDL-C (32 vs. 51 %; 
P < 0.001) and Apo B (33 vs. 40 %; P = 0.001) lipid targets 
when compared to those with high ASCVD risk status.
In MetS patients with very high ASCVD risk status 
(Fig. 3), females were less likely to attain HDL-C (27 vs. 
36 %; P < 0.001), LDL-C (19 vs. 27 %; P < 0.001) and Apo 
B (30 vs. 35 %; P =  0.009) lipid targets when compared 
to males. However, there were no significant differences 
in lipid target achievements between genders in MetS 
patients with high ASCDV risk status (Fig. 4).
Discussion
To our best knowledge this the first study to assess the 
lipid attainment goals in patients with MetS in the Ara-
bian Gulf. The prevalence of MetS was 71 % in patients on 
LLDs in the Arabian Gulf. MetS was more prevalent in the 
Gulf citizens, females and patients with very high ASCVD 
risk status. Patients with MetS were significantly less likely 
to attain their LDL-C (27 vs. 37 %; P < 0.001), non HDL-C 
(35 vs. 55 %; P < 0.001) and apo B (35 vs. 54 %; P < 0.001) 
targets compared to patients without MetS.
MetS is defined as a cluster of cardiovascular risk fac-
tors including central obesity, raised serum TG, reduced 
HDL-C, glucose intolerance, and hypertension [5, 9]. 
Additional abnormalities like the pro-inflammatory and 
pro-thrombotic factors are considered part of the con-
stellation of risk factors in MetS [5, 11], that were not 
measured in the current study. There are several guide-
line definitions of MetS [12], The calculation of the 
MetS prevalence in the current study was based on the 
harmonized definition developed by the a joint state-
ment of the International Diabetes Federation (IDF) Task 
Force on Epidemiology and Prevention, National Heart, 
Lung and Blood Institute⁄American Heart Association 
(NHLBI⁄AHA), the World Heart Federation, the Inter-
national Atherosclerosis Society, and the International 
Association for the Study of Obesity [9].
Insulin resistance plays a major role in lipid derange-
ment in patients with MetS, which is characterized by 
both quantitative dyslipidemia (high TG and low HDL-
C) and qualitative dyslipidemia (small, dense, apo B-100-
rich LDL). These phenotypes of atherogenic dyslipidemia 
in the presence or absence of increased levels of LDL-C is 
the most frequent dyslipidemia observed in patients with 
MetS and are strongly associated with atherosclerosis 
and premature coronary artery disease (CAD) [12–18]. In 
insulin resistance, there is an increase in free fatty acids 
(FFAs) flux to the liver that stimulate the synthesis of 
very low density lipoprotein (VLDL) particles and results 
in high TG levels and Apo B particles in plasma. Insulin 
resistance can also impair the lipolysis of VLDL parti-
cles that leads to an accumulation of triglyceride-rich 
remnant lipoproteins (VLDL-remnants) and subsequent 
transfer of cholesterol esters in exchange for triglycerides 
from the HDL particles to the triglyceride-rich remnant 
through the action of cholesterol ester transfer protein 
(CETP). This will results in smaller HDL particles and 
low levels of HDL-C [19–23]. Moreover, insulin resist-
ance is associated with an increase in C-reactive protein 
(CRP), a marker of inflammation which has been shown 
to increase linearly with the number of metabolic syn-
drome components present [24], associated with a higher 
risk of developing diabetes [25, 26] and CAD [27].
MetS identifies people at a higher risk of CVD and 
diabetes than the general population. MetS is a five-fold 
increased risk of diabetes, a two-fold increase in car-
diovascular outcomes and 1.5-fold increase in all-cause 
mortality according to the recent meta-analysis [4, 16, 
28]. In our study, 32 % of the MetS cohort carried three 
of the major cardiovascular risk factors. Moreover, MetS 
was observed in 81 % of patients with very high ASCVD 
compared to 20 % of high ASCVD risk status. Therefore, 
this highlights the high cardiovascular risk profile of our 
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Table 1 Demographic and clinical characteristics stratified by metabolic syndrome
As per recent unified definition by the International Diabetes Federation (IDF) and the American Heart Association/National Heart, Lung and Blood Institute (AHA/
NHLBI) using the modified National Cholesterol Education Program–Adult Treatment Panel III (NCEP ATP III) guidelines, MetS was defined as having 3 or more of the 
following criteria: (1) increased abdominal obesity (waist circumference of ≥94 cm for men and ≥80 cm for women for Middle Eastern (Mediterranean/European) 
populations), (2) elevated triglycerides of ≥150 mg/dL (1.7 mmol/L), (3) reduced HDL‑C of <40 mg/dL (1.04 mmol/L) for males and <50 mg/dL (1.3 mmol/L) for 
females, (4) elevated BP ≥130 mmHg for systolic and/or ≥85 mmHg for diastolic, and (5) elevated fasting blood glucose of ≥100 mg/dL (5.6 mmol/L)
Criteria for ASCVD risk status was adapted from the National Lipid Association criteria for atherosclerotic cardiovascular disease. High risk group included patients with 
≥3 major ASCVD risk factors, diabetes mellitus (type 1 or 2) with 0/1 major ASCVD risk factor and LDL‑C ≥190 mg/dL (5.02 mmol/L) (severe hypercholesterolemia). 
Very high risk group included ASCVD (CHD, PAD, CVD), diabetes mellitus with ≥2 other major ASCVD risk factors
Despite the lack of a recommended HDL‑C goal by guidelines, satisfactory HDL‑C was defined as <40 mg/dL (1.04 mmol/L) for males or <50 mg/dL (1.3 mmol/L) for 
females. Therapeutic lipoprotein targets for the high risk patients were LDL‑C <2.6 mmol/L, apo B <0.90 g/L and non‑HDL‑C <3.3 mmol/L. For the highest risk group 
therapeutic lipoprotein targets were LDL‑C <1.8 mmol/L, apo B <0.80 g/L and non‑HDL‑C <2.6 mmol/L
BP goals were adapted from the new JNC‑8 2014 Hypertension Guideline Management Algorithm. BP goals for those without diabetes mellitus (DM) and ≥60 years 
and those <60 years were <150/90 mmHg and <140/90 mmHg, respectively. For those with DM irrespective of age, the BP goal was <140/90 mmHg
MetS metabolic syndrome, SD standard deviation, BMI body mass index, CHD coronary heart disease, PAD peripheral arterial disease, CVD cardiovascular disease, 
ASCVD atherosclerotic cardiovascular disease, TC total cholesterol, LDL‑C low‑density lipoprotein cholesterol, HDL‑C high‑density lipoprotein cholesterol, Apo B 
apolipoprotein B, TG triglyceride
Characteristic, n (%) unless specified otherwise All (N = 4171) No MetS (n = 1223) 29 % Mets (n = 2948) 71 % P value
Gulf citizen 3215 (77 %) 874 (71 %) 2341 (79 %) <0.001
Female gender 1711 (41 %) 366 (30 %) 1345 (46 %) <0.001
Age, mean ± SD, years 57 ± 11 57 ± 12 57 ± 11 0.620
Weight, mean ± SD, kg 82 ± 17 78 ± 17 84 ± 17 <0.001
Waist circumference, mean ± SD, cm 104 ± 14 99 ± 14 106 ± 13 <0.001
BMI, mean ± SD, kg/m2 31 ± 7 29 ± 6 32 ± 7 <0.001
BMI >30 kg/m2 2219 (53 %) 484 (40 %) 1735 (59 %) <0.001
Current smoker 517 (12 %) 168 (14 %) 349 (12 %) 0.090
Hypertension 2906 (70 %) 750 (61 %) 2156 (73 %) <0.001
Coronary heart disease 1511 (36 %) 554 (45 %) 957 (32 %) <0.001
Peripheral vascular disease 142 (3.4 %) 52 (4.3 %) 90 (3.1 %) 0.052
Cerebrovascular disease 183 (4.4 %) 53 (4.3 %) 130 (4.4 %) 0.913
Diabetes mellitus 3205 (77 %) 768 (63 %) 2437 (83 %) <0.001
HbA1c, mean ± SD,  % 8.62 ± 3.79 7.84 ± 2.61 8.88 ± 4.06 <0.001
HbA1c <7 % 820 (26 %) 320 (42 %) 500 (21 %) <0.001
ASCVD risk status
High risk 910 (22 %) 335 (27 %) 575 (20 %) <0.001
Very high risk 3261 (78 %) 888 (73 %) 2373 (81 %) <0.001
Dyslipidaemic therapy
Statin monotherapy 3928 (94 %) 1146 (94 %) 2782 (94 %) 0.218
Statin combination 202 (4.8 %) 67 (5.5 %) 135 (4.6 %) 0.486
Others 41 (1.0 %) 10 (0.8 %) 31 (1.1 %) 0.404
Lipid levels on treatment, mean ± SD, mmol/L, unless specified otherwise
TC 4.31 ± 1.11 4.15 ± 1.08 4.38 ± 1.12 <0.001
LDL‑C 2.54 ± 0.94 2.43 ± 0.95 2.58 ± 0.93 <0.001
HDL‑C 1.15 ± 0.31 1.30 ± 0.32 1.10 ± 0.28 <0.001
Apo B, g/L 0.92 ± 0.27 0.84 ± 0.26 0.95 ± 0.27 <0.001
Non‑HDL‑C 3.16 ± 1.09 2.85 ± 1.01 3.28 ± 1.09 <0.001
TG 1.75 ± 1.27 1.19 ± 0.46 1.98 ± 1.42 <0.001
Lipid goal attainments, n (%)
HDL‑C goal 1952 (47 %) 963 (79 %) 989 (34 %) <0.001
LDL‑C goal 1258 (30 %) 449 (37 %) 809 (27 %) <0.001
Apo B goal 1676 (40 %) 658 (54 %) 1018 (35 %) <0.001
Non‑HDL‑C goal 1715 (41 %) 673 (55 %) 1042 (35 %) <0.001
Blood pressure (BP), mean ± SD unless specified otherwise
Systolic BP, mmHg 133 ± 19 125 ± 17 136 ± 18 <0.001
Diastolic BP, mmHg 79 ± 10 75 ± 10 80 ± 10 <0.001
BP control, n (%) 2497 (60 %) 957 (78 %) 1540 (52 %) <0.001
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patients and the need for more intensive risk factors 
stratification and treatment in this population.
The management of MetS should focus on reduc-
ing both short and long term risk of developing subse-
quent cardiovascular events. The treatment should focus 
on optimal controlling of the various components of 
MetS. Life style modifications through weight loss, diet 
and exercise [6] should be the first line intervention in 
patients with MetS. However, in patients with high, very 
high ASCVD risk and in patients who fail life style inter-
vention pharmacological therapies should be considered 
to control atherogenic dyslipidemia [8, 29, 30], diabetes 
[31], hypertension [10] and current guidelines for their 
management should be followed. For the treatment of 
atherogenic dyslipidemia, statins are recommended as 
the first line therapy. Although currently there are no 
clinical trials addressing the cardiovascular outcomes 
of LLDs on patients with the MetS, nevertheless, in the 
subgroup of patients with MetS, clinical trials showed 
benefits from LLDs particularly statins on reducing car-
diovascular events that is considered similar or greater, 
compared with overall study populations [32–35].
Moreover, in the Treating to New Target study (TNT) 
trial, in the subgroup of patients with MetS, CAD and 
no diabetes there was a significant additional benefit on 
cardiovascular events when high dose atorvastatin of 
80 mg was used compared to the low atorvastatin dose of 
10 mg [32]. The use of combination therapy to optimize 
other lipid targets beyond LDL-C like non HDL-C, Apo 
B, TG and HDL-C may be considered in treating athero-
genic dyslipidemia in MetS. Non HDL-C is considered 
to be a better predictor of CV risk and therapeutic target 
Fig. 1 Number of metabolic syndrome (MetS) risk factors (increased 
abdominal obesity, elevated triglycerides, reduced HDL‑C, elevated 
blood pressure, and elevated blood glucose) in atherosclerotic 
cardiovascular disease (ASCVD) risk patients (N = 4171). As per recent 
unified definition by the International Diabetes Federation (IDF) and 
the American Heart Association/National Heart, Lung and Blood 
Institute (AHA/NHLBI) using the modified National Cholesterol Educa‑
tion Program–Adult Treatment Panel III (NCEP ATP III) guidelines, 
MetS was defined as having three or more of the following criteria: 
(1) increased abdominal obesity (waist circumference of ≥94 cm for 
men and ≥80 cm for women for Middle Eastern (Mediterranean/
European) populations), (2) elevated triglycerides of ≥150 mg/
dL (1.7 mmol/L), (3) reduced HDL‑C of <40 mg/dL (1.04 mmol/L) 
for males and <50 mg/dL (1.3 mmol/L) for females, (4) elevated BP 
≥130 mmHg for systolic and/or ≥85 mmHg for diastolic, and (5) 
elevated fasting blood glucose of ≥100 mg/dL (5.6 mmol/L). Criteria 
for ASCVD risk status was adapted from the National Lipid Associa‑
tion criteria for atherosclerotic cardiovascular disease. High risk group 
included patients with ≥3 major ASCVD risk factors, diabetes mellitus 
(type 1 or 2) with 0/1 major ASCVD risk factor and LDL‑C ≥190 mg/
dL (5.02 mmol/L) (severe hypercholesterolemia). Very high risk group 
included ASCVD (CHD, PAD, CVD), diabetes mellitus with ≥2 other 
major ASCVD risk factors
Fig. 2 Lipid target achievements (HDL‑C, LDL‑C, non HDL‑C and Apo 
B) in metabolic syndrome patients stratified by atherosclerotic cardio‑
vascular disease (ASCVD) risk status (N = 2948). HDL‑C high‑density 
lipoprotein cholesterol, LDL‑C low‑density lipoprotein cholesterol, 
Apo B apolipoprotein B. As per recent unified definition by the Inter‑
national Diabetes Federation (IDF) and the American Heart Associa‑
tion/National Heart, Lung and Blood Institute (AHA/NHLBI) using the 
modified National Cholesterol Education Program–Adult Treatment 
Panel III (NCEP ATP III) guidelines, MetS was defined as having three 
or more of the following criteria: (1) increased abdominal obesity 
(waist circumference of ≥94 cm for men and ≥80 cm for women for 
middle eastern (Mediterranean/European) populations), (2) elevated 
triglycerides of ≥150 mg/dL (1.7 mmol/L), (3) reduced HDL‑C of 
<40 mg/dL (1.0 mmol/L) for males and <50 mg/dL (1.3 mmol/L) for 
females, (4) elevated BP ≥130 mmHg for systolic and/or ≥85 mmHg 
for diastolic, and (5) elevated fasting blood glucose of ≥100 mg/
dL (5.6 mmol/L). Criteria for ASCVD risk status was adapted from the 
National Lipid Association criteria for atherosclerotic cardiovascular 
disease. High risk group included patients with ≥3 major ASCVD risk 
factors, diabetes mellitus (type 1 or 2) with 0–1 major ASCVD risk fac‑
tors, LDL‑C ≥190 mg/dL (severe hypercholesterolemia). Very high risk 
group included ASCVD (CHD, PAD, CVD), diabetes mellitus with ≥2 
other major ASCVD risk factors. Despite the lack of a recommended 
HDL‑C goal by guidelines, satisfactory HDL‑C was defined as <40 mg/
dL (1.03 mmol/L) for males or <50 mg/dL (1.29 mmol/L) for females. 
Therapeutic lipoprotein targets for the highest risk group were 
LDL‑C <1.8 mmol/L, apo B <0.80 g/L and non‑HDL‑C <2.6 mmol/L
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than LDL-C, particularly in patients with diabetes and 
MetS, and therefore the NLA in their recent guideline, 
have placed non HDL-C ahead of LDL-C as a therapeu-
tic target [8]. Apart from adding ezetimibe to statins for 
combination therapy [36], other combination therapies 
like fibrates and niacin [37] have failed to show additional 
benefits in reducing cardiovascular events. Nonetheless, 
adding fibrates particularly fenofibrate to statins, have 
proven to be safe and effective in reducing cardiovascular 
events in subgroup of patients with obesity, high TG and 
low HDL-C [38, 39] and therefore, should be considered 
to treat high risk patients with atherogenic dyslipidemia 
when high dose statins failed to achieve the lipid thera-
peutic targets.
In our study MetS patients with very high ASCVD 
risk status were less likely to attain LDL-C (24 vs. 43 %; 
P < 0.001) and non HDL-C (32 vs. 51 %; P < 0.001) lipid 
targets when compared with those with high ASCVD 
risk status. Compared to the Dyslipidemia International 
Study of China (DYSIS-China), which was an observa-
tional study of 25,697 patients, in which 37 % had CAD, 
57 % had diabetes and over one-third had MetS. LDL-C 
goal was achieved in 47  % of patients with MetS com-
pared to 69 % in those without the MetS (P < 0.001). Non 
HDL-C goals were achieved in 51 % of patients with MetS 
compared to 72 % in those without the MetS (P < 0.001). 
Among very high-risk individuals, only 26  % achieved 
their LDL-C goal and 42  % attained their non HDL-C 
goal [40]. Similar to the DYSIS-China study, the current 
Fig. 3 Lipid target achievements (HDL‑C, LDL‑C, non HDL‑C and Apo 
B) in patients with metabolic syndrome and very high atheroscle‑
rotic cardiovascular disease (ASCVD) risk status stratified by gender 
(N = 2373). HDL‑C high‑density lipoprotein cholesterol, LDL‑C low‑
density lipoprotein cholesterol, Apo B, apolipoprotein B. As per recent 
unified definition by the International Diabetes Federation (IDF) and 
the American Heart Association/National Heart, Lung and Blood Insti‑
tute (AHA/NHLBI) using the modified National Cholesterol Education 
Program–Adult Treatment Panel III (NCEP ATP III) guidelines, MetS was 
defined as having 3 or more of the following criteria: (1) increased 
abdominal obesity (waist circumference of ≥94 cm for men and 
≥80 cm for women for Middle Eastern (Mediterranean/European) 
populations), (2) elevated triglycerides of ≥150 mg/dL (1.7 mmol/L), 
(3) reduced HDL‑C of <40 mg/dL (1.0 mmol/L) for males and <50 mg/
dL (1.3 mmol/L) for females, (4) elevated BP ≥130 mmHg for systolic 
and/or ≥85 mmHg for diastolic, and (5) elevated fasting blood glu‑
cose of ≥100 mg/dL (5.6 mmol/L). Criteria for ASCVD risk status was 
adapted from the National Lipid Association criteria for atheroscle‑
rotic cardiovascular disease. High risk group included patients with 
≥3 major ASCVD risk factors, diabetes mellitus (type 1 or 2) with 0–1 
major ASCVD risk factors, LDL‑C ≥190 mg/dL (severe hypercholes‑
terolemia). Very high risk group included ASCVD (CHD, PAD, CVD), 
diabetes mellitus with ≥2 other major ASCVD risk factors. Despite the 
lack of a recommended HDL‑C goal by guidelines, satisfactory HDL‑C 
was defined as <40 mg/dL (1.03 mmol/L) for males or <50 mg/dL 
(1.29 mmol/L) for females. Therapeutic lipoprotein targets for the 
highest risk group were LDL‑C <1.8 mmol/L, apo B <0.80 g/L and 
non‑HDL‑C <2.6 mmol/L
Fig. 4 Lipid target achievements (HDL‑C, LDL‑C, non HDL‑C and Apo 
B) in patients with metabolic syndrome and high atherosclerotic car‑
diovascular disease (ASCVD) risk status stratified by gender (N = 575). 
HDL‑C high‑density lipoprotein cholesterol, LDL‑C low‑density 
lipoprotein cholesterol, Apo B apolipoprotein B. As per recent unified 
definition by the International Diabetes Federation (IDF) and the 
American Heart Association/National Heart, Lung and Blood Institute 
(AHA/NHLBI) using the modified National Cholesterol Education 
Program–Adult Treatment Panel III (NCEP ATP III) guidelines, MetS was 
defined as having 3 or more of the following criteria: (1) increased 
abdominal obesity (waist circumference of ≥94 cm for men and 
≥80 cm for women for Middle Eastern Mediterranean/European) 
populations), (2) elevated triglycerides of ≥150 mg/dL (1.7 mmol/L), 
(3) reduced HDL‑C of <40 mg/dL (1.0 mmol/L) for males and <50 mg/
dL (1.3 mmol/L) for females, (4) elevated BP ≥130 mmHg for systolic 
and/or ≥85 mmHg for diastolic, and (5) elevated fasting blood glu‑
cose of ≥100 mg/dL (5.6 mmol/L). Criteria for ASCVD risk status was 
adapted from the National Lipid Association criteria for atheroscle‑
rotic cardiovascular disease. High risk group included patients with 
≥3 major ASCVD risk factors, diabetes mellitus (type 1 or 2) with 0–1 
major ASCVD risk factors, LDL‑C ≥190 mg/dL (severe hypercholes‑
terolemia). Very high risk group included ASCVD (CHD, PAD, CVD), 
diabetes mellitus with ≥2 other major ASCVD risk factors. Despite the 
lack of a recommended HDL‑C goal by guidelines, satisfactory HDL‑C 
was defined as <40 mg/dL (1.03 mmol/L) for males or <50 mg/dL 
(1.29 mmol/L) for females. Therapeutic lipoprotein targets for the high 
risk patients were LDL‑C <2.6 mmol/L, apo B <0.90 g/L and non‑HDL‑
C <3.3 mmol/L
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study showed that the majority of MetS patients were on 
statin therapy (94 %), the use of other non-statin (1.1 %) 
or combination therapies (4.6 %) were low [7]. Therefore, 
the recommendation from both studies is to increase 
the awareness of both patients and clinicians regard-
ing the atherogenic dyslipidemia and increased ASCVD 
risk associated with the MetS. In order to improve thera-
peutic lipid goals attainment and reduce ASCVD risk 
in MetS, effective strategies need to be developed and 
implemented and should primarily focused on life style 
modifications and to use more intensive LLDs and com-
bination therapies in patients with very-high risk ASCVD 
risk status.
In a systematic review conducted by Mabry and col-
leagues, the reported prevalence of the MetS in the gen-
eral population in the Arabian Gulf is 10–15  % higher 
than in most developed countries and it is higher in 
women (32.1–42.7 %) than men (20.7–37.2 %) [1]. There 
was no report concerning statin use and the attainment 
of lipid targets in this systematic review [1]. We observed 
similar higher prevalence of MetS in women than men 
(46 vs. 30 %; P < 0.001). Moreover; in our study females 
with MetS and very high ASCVD risk status were less 
likely to attain lipid targets when compared to males. 
The gap in lipid goals between men and women in our 
study may be explained by the high prevalence of T2DM 
and MetS in women compared to men. In addition, these 
findings may be associated with other factors like base-
line lipid levels, socioeconomic status, marital status and 
the dosage of statin [41–43]. The prevalence of MetS in 
our study (71  %) was higher than that seen in the Gulf 
RACE study (46 %), in patients with ACS in the Arabian 
Gulf. In this study they observed higher statin usage 
among patients with MetS compared to patients with no 
MetS (83 vs. 79  %) but there was no report concerning 
the attainment of lipid targets [2, 3]. The difference in the 
prevalence of metabolic syndrome between these studies 
can be explained by factors like the type of the population 
understudy, the number of cardiovascular co-morbidities 
and other associated risk factors and the difference in the 
criteria used to define MetS.
Our findings provide a useful overview of current lipid 
management and treatment outcomes in patients with 
MetS in the Middle East. However, they study is not with-
out limitations; it is an observational cross-sectional trial 
that did not assess long-term outcomes. A prospective 
follow-up study is required to evaluate medical treatment 
and attainment in relation to mortality in patients treated 
with LLDs. The population studied is relatively small and 
considerable variability in practice patterns across the 
Arabian Gulf exists, and probably even among study sites, 
and therefore caution should be exercised when extrapo-
lating the results to the general population. In addition, 
the population included only patients who were already 
on LLDs. It was not clear what proportion of eligible 
patients with appropriate risk factors were offered LLDs 
in different countries. Such information would be impor-
tant to evaluate the overall burden of the disease among 
untreated patients in various countries.
Conclusion
This study has demonstrated that MetS is highly preva-
lent and is associated with low attainment of lipid thera-
peutic targets in the Arabian Gulf. Furthermore, women 
and those with very high ASCVD risk were also less likely 
to attain their lipid targets. In order to improve thera-
peutic lipid goal attainment and reduce ASCVD risk in 
MetS in the Arabian Gulf region, effective strategies need 
to be developed and implemented and should primarily 
be focused on life style modifications and more intensive 
LLDs and combination therapies in patients with high 
risk ASCVD risk status.
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